Home Companies Catalysts Deep Dives
Vemlidy tenofovir alafenamide APPROVED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaInfectious Disease
Launch2016-11-10
US LOE2031-11-10
Peak Sales Est$1200M
Formulations[{"id":"vemlidy-tablet","route":"PO","setting":"PATIENT_SELF","frequency":"Once daily","is_primary":
Companies
GILD (ORIGINATOR)100%
Mechanism: Nucleotide reverse transcriptase inhibitor (NtRTI)
Expert: Prodrug of tenofovir that inhibits HIV reverse transcriptase.
Everyday: Blocks HIV enzyme needed to copy viral genetic material.
Targets: ["HIV RT"]
Revenue History
PeriodRevenue ($M)
2023$1,135M
2024$1,288M
Q4 2025$287M
2025$1,050M
Programs (1)
IndicationStageKey StudyRegional Status
Chronic HBVAPPROVEDGS-US-320-0108/0110[{"stage":"APPROVED","region":"US","approval_date":"2016-11-10"}]
Notes
HBV treatment with improved renal/bone safety vs older tenofovir.
Data from Supabase · Updated 2026-03-24